Patents Assigned to GlaxoSmithKline Intellectual Property Development Limited
-
Patent number: 11577082Abstract: Devices and methods for the stimulation of neural signaling of an apical splenic nerve, the device having a transducer for placement on or around the apical splenic nerve, and a signal generator to generate a signal that stimulates or inhibits the neural activity of the apical splenic nerve to produce a physiological response. The transducer has at least one electrode, and the signal generator is a voltage or current source. The stimulation electrical signal has a frequency of between 1 Hz and 50 Hz.Type: GrantFiled: November 8, 2017Date of Patent: February 14, 2023Assignees: Galvani Bioelectronics Limited, GlaxoSmithKline Intellectual Property Development Limited, Université de Nice Sophia-Antipolis, Centre Nationale de La Recherche ScientifiqueInventors: Philippe Blancou, Nicolas Glaichenhaus, Arun Sridhar
-
Patent number: 11566347Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.Type: GrantFiled: May 12, 2020Date of Patent: January 31, 2023Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Valeriu Damian, Austin Keith Doyle, Laura Maria Halo, Emma R. Harding, Xuan Hong, Alan Peter Lewis, Mark Uden
-
Patent number: 11555040Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.Type: GrantFiled: April 16, 2018Date of Patent: January 17, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Andrew Baxter, Sophie Marie Bertrand, Matthew Campbell, Kenneth David Down, Curt Dale Haffner, Julie Nicole Hamblin, Zoe Alicia Henley, William Henry Miller, Eric Philippe Andre Talbot, Jonathan Andrew Taylor
-
Patent number: 11547704Abstract: The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof.Type: GrantFiled: June 11, 2020Date of Patent: January 10, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Raghava Reddy Kethiri, Biswajit Kalita
-
Publication number: 20220411425Abstract: The invention relates to a compound having the structure: or a pharmaceutically acceptable salt thereof, along with pharmaceutical compositions and therapeutic methods thereof.Type: ApplicationFiled: June 1, 2021Publication date: December 29, 2022Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, VIIV HEALTHCARE COMPANYInventors: Martha Alicia DE LA ROSA, John F. MILLER, B. Narasimhulu NAIDU, Vicente SAMANO, David TEMELKOFF, Emile Johann VELTHUISEN
-
Patent number: 11535833Abstract: The present disclosure provides engineered carboxyesterase enzymes that have the ability to catalyze amide bond formation. Also provided are polynucleotides encoding the carboxyesterase enzymes, host cells capable of expressing the engineered carboxyesterase enzymes, and methods of using the engineered carboxyesterase enzymes to make commercially valuable amides. Also provided are amides that are made using the engineered carboxyesterase enzymes.Type: GrantFiled: December 13, 2018Date of Patent: December 27, 2022Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Kristin K. Brown, Brent M. Dorr, Douglas E. Fuerst, Katherine Joyce Honicker, Lydia Sanchez Jordan, James Patrick Morrison, Nikolay V. Plotnikov, Markus Schober, Rama Voladri
-
Patent number: 11530238Abstract: The present invention relates to a method of purifying a recombinant polypeptide from Host Cell Proteins (HCP), the method comprising: (a) applying a solution comprising the recombinant polypeptide and HCP to a superantigen chromatography solid support, (b) washing the superantigen chromatography solid support with a wash buffer comprising caprylate and arginine; and (c) eluting the recombinant polypeptide from the superantigen chromatography solid support.Type: GrantFiled: September 6, 2017Date of Patent: December 20, 2022Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Andre C. Dumetz, Kent E. Goklen, Nicholas E. Levy, Jessica Rachel Molek, Andrew S. Thomson, Kenneth G. Yancey
-
Patent number: 11492361Abstract: The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.Type: GrantFiled: October 5, 2020Date of Patent: November 8, 2022Assignees: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare CompanyInventors: Richard M. Dunham, David Margolis, Vincent Wing-Fai Tai, Jun Tang
-
Patent number: 11485710Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.Type: GrantFiled: January 22, 2021Date of Patent: November 1, 2022Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Claude-Marie Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski
-
Patent number: 11479607Abstract: The present disclosure relates to compositions for treating CD96 mediated diseases, and related methods.Type: GrantFiled: November 19, 2021Date of Patent: October 25, 2022Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Yan Y. Degenhardt, Jun Guan, Kenneth William Hance, Peter Joseph Morley
-
Publication number: 20220324875Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.Type: ApplicationFiled: April 16, 2018Publication date: October 13, 2022Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Andrew BAXTER, Sophie Marie BERTRAND, Matthew CAMPBELL, Kenneth David DOWN, Curt Dale HAFFNER, Julie Nicole HAMBLIN, Zoe Alicia HENLEY, William Henry MILLER, Eric Philippe Andre TALBOT, Jonathan Andrew TAYLOR
-
Publication number: 20220315556Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.Type: ApplicationFiled: May 10, 2019Publication date: October 6, 2022Applicant: Glaxosmithkline Intellectual Property Development LimitedInventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Huiping Amy Guan, Yan Hu, Aaron Bayne Miller, Donghui Qin, Chengde Wu, Zhiliu Zhang, Xiaojuan Lin
-
Patent number: 11453657Abstract: The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding compositions, and methods and/or uses in therapy, for example in the treatment of parasitic infections such as malaria, in particular infection by Plasmodium falciparum.Type: GrantFiled: January 23, 2019Date of Patent: September 27, 2022Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Maria Isabel Castellote Alvaro, Maria Luisa León Diaz, Jose Ignacio Martin Hernando
-
Patent number: 11434032Abstract: A modular production system including a plurality of production modules connected in a linear series to form a production tunnel, and collectively defining a production channel, and wherein at least one fluid inlet port defined along the production tunnel, said inlet port is in fluid communication with a pressurized fluid source, whereby influx of fluid from said fluid source through said fluid inlet port acts to maintain the fluid pressure within the production channel at a higher pressure than the atmospheric pressure outside of the production tunnel; and wherein one of said production modules positioned between said proximal-most and distal-most production modules comprises a depyrogenator and/or sterilization module, comprising a transparent tubular body, and an irradiation source positioned external to said transparent tubular body, said irradiation source capable of heating the internal environment of the depyrogenation and/or sterilization module to a temperature sufficient to depyrogenate or sterilizeType: GrantFiled: December 11, 2018Date of Patent: September 6, 2022Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventor: Francesco Sanmartin
-
Patent number: 11427643Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.Type: GrantFiled: May 21, 2020Date of Patent: August 30, 2022Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Lewis Lee Brayshaw, Michael Menteith Hann, Christopher Herring, Carlos Martinez Fleites, Markus Alexander Queisser
-
Patent number: 11401334Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).Type: GrantFiled: September 12, 2018Date of Patent: August 2, 2022Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Sanjay Khandekar, Patrick Mayes, Joanna Opalinska
-
Publication number: 20220213076Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of metabolic disorders (e.g. Prader-Willi syndrome, metabolic syndrome, insulin resistance, impaired glucose tolerance, prediabetes, diabetes mellitus (e.g., type II diabetes mellitus), dysglycemia (e.g., hyperglycemia), obesity (e.g., obesity caused by Prader-Willi syndrome), increased adiposity, poor glycemic control, hyperphagia, impaired satiety, dyslipidemia (e.g., atherogenic dyslipidemia), hepatic steatosis (e.g., non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis))), psychiatric disorders (e.g., eating disorders (e.g., bulimia nervosa, binge eating disorder, night-time eating syndrome), substance related disorders (e.g., addiction disorders (e.g.Type: ApplicationFiled: March 24, 2022Publication date: July 7, 2022Applicant: Glaxosmithkline Intellectual Property Development LimitedInventors: Anish Bandyopadhyay, Mui Cheung, Hilary Schenck Eidam, Hemant Joshi, Dai-Shi Su
-
Patent number: 11377440Abstract: Disclosed are compounds having the formula: (I) wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, R17, Rx, and Ry are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.Type: GrantFiled: October 4, 2018Date of Patent: July 5, 2022Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: David T. Fosbenner, Todd L. Graybill, Jianxing Kang, Bryan W. King, Yunfeng Lan, Lara Kathryn Leister, Mukesh K. Mahajan, John F. Mehlmann, Angel I. Morales-Ramos, George Scott Pesiridis, Joshi M. Ramanjulu, Joseph J. Romano, Stuart Paul Romeril, Mark J. Schulz, Huiqiang Zhou, Junya Qu
-
Patent number: 11365190Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.Type: GrantFiled: January 25, 2021Date of Patent: June 21, 2022Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Adam Kenneth Charnley, Gren Z. Wang, Joseph J. Romano
-
Patent number: 11353458Abstract: Methods are provided for determining prognosis of multiple myeloma in a patient by measuring expression of BCMA in a sample. Also provided are methods for treating multiple myeloma by measuring expression of BCMA in a sample and administering an effective amount of an antigen binding protein that binds BCMA. Also provided are kits for measuring BCMA expression in a sample.Type: GrantFiled: October 28, 2016Date of Patent: June 7, 2022Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Danton Bounds, Jenny L. Craigen, William E. Fieles, Fiona M. Germaschewski, Gaelle Herledan, Lydia Lee, Patrick A. Mayes, Lee McCahon, Katherine (Nee Sully) Nevin, Jennifer Paterson, Manuel Rodriguez-Justo, Laura M. Seestaller-Wehr, James Tunstead, Kwee L. Yong